SUMMARY
Extradural administration of either local anaesthetics or opioids has been shown to be effective for pain management in patients with thoracic injury [1, 2] and in high risk patients requiring intensive care after upper abdominal surgery [3] . However, these patients may be at risk of developing multiple organ failure (MOF).
Extradural administration of local anaesthetics may be associated with systemic toxic effects [4] . Differences in the plasma concentrations of local anaesthetics may be caused by organ dysfunction [5] ; there are no data on the plasma concentrations of local anaesthetics during extradural analgesia in patients developing MOF. We have measured, therefore, plasma concentrations of lignocaine during continuous extradural infusion of lignocaine in patients with and without MOF.
PATIENTS AND METHODS
We have studied patients admitted to our intensive care unit with chest wall trauma or after major upper abdominal surgery. All had required ventilatory support for adequate gas exchange and thoracic extradural analgesia was considered appropriate for pain management. Organ failure was defined as severity grade 2 in the multiple organ failure score originally described by Goris and colleagues [6] . Multiple organ failure was present when at least twoorgan failure was present. Sepsis was diagnosed according to the definition of Montgomery and colleagues [7] . Patients were excluded from the study if they had neurological injury, spinal injury, sepsis or coagulopathy.
The study was explained in detail to each patient, and informed consent was obtained for all procedures.
All patients were placed in a lateral decubitus position and a-16-gauge Tuohy needle was introduced in the extradural space at the T5-6 or T6-7 level. A therapeutic dose of 2% lignocaine 10 ml without adrenaline was injected extradurally and an 18-gauge extradural catheter was advanced approximately 4-5 cm into the extradural space. A continuous infusion of 2 % lignocaine 0.5-0.6 ml kg" ) without adrenaline [8, 9] was begun 3-5 min after the test dose had been given. In four patients, an additional extradural infusion of fentanyl 1 ugkg" 1 h" 1 [10] was required to achieve adequate analgesia (table I) .
Arterial blood samples were collected 4, 8, 24 and 48 h after the continuous infusion of lignocaine was started and their plasma concentrations of lignocaine analysed immediately in duplicate by fluorescencepolarization immunoassay as described previously [11, 12] , using commercially available immunoassay kits (Abbot, TDx, Chicago, IL).
CASE REPORTS

Patients with MOF
Patient No. 1. A 52-yr-old male with acute alcoholrelated necrotizing pancreatitis underwent lapar- 
RESULTS
There were no adverse local or systemic effects of lignocaine in either the MOF or the non-MOF patients.
We terminated the study because four patients developing MOF had plasma lignocaine concentrations which exceeded the stated lower toxic concentration of 3 ug ml" 1 [13] . The plasma lignocaine concentrations for patients with and without MOF are shown in table II. 
DISCUSSION
We have found that administration of a continuous extradural infusion of 2 % lignocaine was associated with toxic plasma concentrations of lignocaine (^ 3 ug ml" 1 ) [13] in patients with MOF. In contrast, plasma lignocaine concentrations remained smaller than toxic values in patients without MOF.
The plasma concentration of a local anaesthetic during continuous extradural infusion is determined mainly by absorption into the systemic circulation, its distribution and its rate of clearance by the liver [14] ; all of these factors may be altered in the presence of MOF. Body weight and renal disease [5] are reported to have minor effects on the elimination of lignocaine, whereas hypovolaemia [15] , cardiovascular disease [16] and hepatic cirrhosis [5] are associated with a decrease in plasma clearance. Clearance of lignocaine is mainly flow dependent [14] . Liver blood flow is determined principally by cardiac output, which in our patients was kept in a higher range (cardiac index > 3.5 litre min" 1 ) to increase oxygen delivery by adequate volume replacement and if necessary by positive inotropic therapy. Thus the presence of either cardiovascular failure or hepatic failure alone may not explain the increased plasma lignocaine concentrations in our MOF patients. Drugs (e.g. H 2 -blockers, sedatives) have been shown to decrease both hepatic blood flow and enzyme activity [17] and these factors may also have reduced lignocaine clearance in our MOF patients (table II) .
Plasma concentrations of lignocaine in our patients without MOF were slightly smaller than those observed in parturients receiving extradural analgesia with a similar continuous infusion of lignocaine [9] . In contrast, plasma concentrations in our MOF patients were greater than those in patients receiving pain relief with i.v. lignocaine infusions [18] . Despite these concentrations, we did not observe any signs of systemic toxicity in our patients with MOF. The relationship between blood concentrations of local anaesthetic to symptoms of toxicity is less clear [19] . Increased protein binding of local anaesthetics in the presence of increased plasma concentrations of local anaesthetics has been shown to exist without signs of serious toxicity in postoperative patients [20] . Changes in the plasma protein profile of our patients were not measured and so a similar mechanism cannot be excluded. The central nervous system toxicity of lignocaine is sensitive to acid-base balance; all our patients had changes varying between mild acidosis and mild alkalosis (table II) . Three of the four MOF patients required additonal i.v. sedation with midazolam that might have masked neurological signs of toxicity.
Although extradural analgesia relieved pain and facilitated weaning from the ventilator, our observations suggest that a continuous extradural infusion of lignocaine should only be considered in intensive care patients without MOF or in the presence of regular monitoring of plasma concentrations of lignocaine.
